Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.

The drug industry offered its first significant sign of pushback against the Trump administration late Tuesday, after a day of dramatic cuts to U.S. public health infrastructure. Drug stocks tumbled ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...